Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s innovative drug development initiative-Group 3 pulmonary hypertension

By sjmartinez • July 1, 2022

Nikkho SM, Richter MJ, Shen E, Abman SH, Antoniou K, Chung J, Fernandes P, Hassoun P, Lazarus HM, Olschewski H, Piccari L, Psotka M, Saggar R, Shlobin OA, Stockbridge N, Vitulo P, Vizza CD, Wort SJ, Nathan SD. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension. Pulm Circ. 2022 Jul 1;12(3):e12127. doi: 10.1002/pul2.12127. PMID: 36016668; PMCID: PMC9395696.

Tags: Epidemiology, interstitial lung disease, prognosis, Publications, pulmonary hypertension, Pulmonary, Critical Care & Sleep Medicine, symptom assessment and management

Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma

Robatel S, Hillen H, Mutisheva I, Müller JC, Wartenberg M, Ma F, Bäriswyl L, Evenepoel J, Scheele CLGJ, Lee DJ, Modlin RL, Kessler U, Nobis[...]

Specific serotonin receptor antagonist reduces murine calcific atherosclerosis

Hon A, Lu M, Demer LL, Tintut Y. Specific serotonin receptor antagonist reduces murine calcific atherosclerosis. Atherosclerosis. 2026 Jan 27;414:120649. doi: 10.1016/j.atherosclerosis.2026.120649. Epub ahead of[...]

Sex does not modify prediction of asthma attacks by clinical risk factors and Type-2 biomarkers

Riemann S, Meulmeester FL, Mailhot-Larouche S, Ramakrishnan S, Wechsler ME, Corren J, Diver SE, Brightling CE, Castro M, Hanania NA, Jackson DJ, Martin N, Laugerud[...]